vs
Side-by-side financial comparison of Seritage Growth Properties (SRG) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
Seritage Growth Properties is the larger business by last-quarter revenue ($4.2M vs $2.2M, roughly 1.9× Instil Bio, Inc.). On growth, Seritage Growth Properties posted the faster year-over-year revenue change (-4.9% vs -19.2%).
Seritage Growth Properties is a U.S.-headquartered publicly traded real estate investment trust. It owns, redevelops, and manages a diversified portfolio of retail, residential, and mixed-use commercial properties across key U.S. markets, leasing spaces to retail, dining, and service sector tenants.
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
SRG vs TIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.2M | $2.2M |
| Net Profit | — | $-8.2M |
| Gross Margin | — | — |
| Operating Margin | — | -426.3% |
| Net Margin | — | -365.3% |
| Revenue YoY | -4.9% | -19.2% |
| Net Profit YoY | 55.2% | 31.1% |
| EPS (diluted) | — | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.2M | $2.2M | ||
| Q3 25 | $4.8M | $2.2M | ||
| Q2 25 | $4.7M | $2.2M | ||
| Q1 25 | $4.6M | $2.2M | ||
| Q4 24 | $4.4M | $2.8M | ||
| Q3 24 | $3.3M | $1.5M | ||
| Q2 24 | $4.2M | $0 | ||
| Q1 24 | $5.8M | $0 |
| Q4 25 | — | $-8.2M | ||
| Q3 25 | $-12.4M | $-13.6M | ||
| Q2 25 | $-28.5M | $-21.4M | ||
| Q1 25 | $-22.2M | $-28.2M | ||
| Q4 24 | — | $-11.9M | ||
| Q3 24 | $-22.0M | $-23.0M | ||
| Q2 24 | $-101.2M | $-14.9M | ||
| Q1 24 | $-19.0M | $-24.3M |
| Q4 25 | — | -426.3% | ||
| Q3 25 | -258.0% | -670.0% | ||
| Q2 25 | -610.2% | -1045.5% | ||
| Q1 25 | -486.9% | -1363.2% | ||
| Q4 24 | — | -426.1% | ||
| Q3 24 | -673.2% | -1582.8% | ||
| Q2 24 | -2366.1% | — | ||
| Q1 24 | -328.7% | — |
| Q4 25 | — | -365.3% | ||
| Q3 25 | -259.6% | -606.0% | ||
| Q2 25 | -612.6% | -954.2% | ||
| Q1 25 | -482.8% | -1257.8% | ||
| Q4 24 | — | -428.8% | ||
| Q3 24 | -675.9% | -1541.9% | ||
| Q2 24 | -2401.0% | — | ||
| Q1 24 | -328.9% | — |
| Q4 25 | — | $-1.13 | ||
| Q3 25 | $-0.24 | $-2.01 | ||
| Q2 25 | $-0.53 | $-3.24 | ||
| Q1 25 | $-0.42 | $-4.32 | ||
| Q4 24 | — | $-1.82 | ||
| Q3 24 | $-0.41 | $-3.54 | ||
| Q2 24 | $-1.82 | $-2.29 | ||
| Q1 24 | $-0.36 | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $48.1M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $331.4M | $113.9M |
| Total Assets | $393.8M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.1M | $6.6M | ||
| Q3 25 | $51.5M | $5.8M | ||
| Q2 25 | $71.8M | $7.7M | ||
| Q1 25 | $94.3M | $15.4M | ||
| Q4 24 | $85.2M | $8.8M | ||
| Q3 24 | $85.6M | $6.7M | ||
| Q2 24 | $86.7M | $6.8M | ||
| Q1 24 | $114.9M | $5.5M |
| Q4 25 | $331.4M | $113.9M | ||
| Q3 25 | $337.7M | $120.4M | ||
| Q2 25 | $351.4M | $131.7M | ||
| Q1 25 | $381.1M | $144.9M | ||
| Q4 24 | $404.5M | $169.4M | ||
| Q3 24 | $417.5M | $176.3M | ||
| Q2 24 | $440.4M | $195.0M | ||
| Q1 24 | $542.4M | $205.8M |
| Q4 25 | $393.8M | $203.5M | ||
| Q3 25 | $558.6M | $211.8M | ||
| Q2 25 | $575.7M | $231.0M | ||
| Q1 25 | $649.7M | $237.4M | ||
| Q4 24 | $677.8M | $263.6M | ||
| Q3 24 | $735.0M | $272.6M | ||
| Q2 24 | $758.3M | $294.3M | ||
| Q1 24 | $914.6M | $306.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.9M | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.9M | $-7.1M | ||
| Q3 25 | $-12.5M | $-10.6M | ||
| Q2 25 | $-12.0M | $-14.8M | ||
| Q1 25 | $-9.2M | $-4.2M | ||
| Q4 24 | $-53.5M | $-10.6M | ||
| Q3 24 | $-15.5M | $-20.1M | ||
| Q2 24 | $-7.5M | $-10.6M | ||
| Q1 24 | $-16.6M | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
